Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Accumulated Depreciation (2020 - 2023)

Candel Therapeutics' Accumulated Depreciation history spans 4 years, with the latest figure at $1.8 million for Q3 2023.

  • For Q3 2023, Accumulated Depreciation changed N/A year-over-year to $1.8 million; the TTM value through Sep 2023 reached $1.8 million, changed N/A, while the annual FY2022 figure was $1.1 million, 220.74% up from the prior year.
  • Accumulated Depreciation for Q3 2023 was $1.8 million at Candel Therapeutics, up from $1.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $1.8 million in Q3 2023 and bottomed at $134000.0 in Q4 2020.
  • The 4-year median for Accumulated Depreciation is $1.2 million (2022), against an average of $1.1 million.
  • The largest annual shift saw Accumulated Depreciation skyrocketed 162.69% in 2021 before it surged 220.74% in 2022.
  • A 4-year view of Accumulated Depreciation shows it stood at $134000.0 in 2020, then surged by 162.69% to $352000.0 in 2021, then soared by 220.74% to $1.1 million in 2022, then soared by 62.98% to $1.8 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Accumulated Depreciation are $1.8 million (Q3 2023), $1.6 million (Q2 2023), and $1.4 million (Q1 2023).